SG11201408168UA - Azetidine and piperidine compounds useful as pde10 inhibitors - Google Patents
Azetidine and piperidine compounds useful as pde10 inhibitorsInfo
- Publication number
- SG11201408168UA SG11201408168UA SG11201408168UA SG11201408168UA SG11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA SG 11201408168U A SG11201408168U A SG 11201408168UA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- amgen
- azetidine
- thousand oaks
- Prior art date
Links
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003053 piperidines Chemical class 0.000 title abstract 2
- 241000219492 Quercus Species 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261659911P | 2012-06-14 | 2012-06-14 | |
| PCT/US2013/045768 WO2013188724A1 (en) | 2012-06-14 | 2013-06-14 | Azetidine and piperidine compounds useful as pde10 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408168UA true SG11201408168UA (en) | 2015-01-29 |
Family
ID=48692687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408168UA SG11201408168UA (en) | 2012-06-14 | 2013-06-14 | Azetidine and piperidine compounds useful as pde10 inhibitors |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US8691986B2 (https=) |
| EP (1) | EP2864317A1 (https=) |
| JP (1) | JP2015519402A (https=) |
| KR (1) | KR20150023417A (https=) |
| CN (1) | CN104619694A (https=) |
| AP (1) | AP2014008136A0 (https=) |
| AR (1) | AR091436A1 (https=) |
| AU (1) | AU2013274153B2 (https=) |
| BR (1) | BR112014031368A2 (https=) |
| CA (1) | CA2875802A1 (https=) |
| CL (1) | CL2014003391A1 (https=) |
| CO (1) | CO7160011A2 (https=) |
| CR (1) | CR20150012A (https=) |
| EA (1) | EA201590014A1 (https=) |
| HK (1) | HK1203935A1 (https=) |
| IL (1) | IL235901A0 (https=) |
| MA (1) | MA37748B1 (https=) |
| MX (1) | MX2014014924A (https=) |
| PE (1) | PE20150348A1 (https=) |
| PH (1) | PH12014502780A1 (https=) |
| SG (1) | SG11201408168UA (https=) |
| TN (1) | TN2014000510A1 (https=) |
| TW (1) | TWI508959B (https=) |
| UY (1) | UY34858A (https=) |
| WO (1) | WO2013188724A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011143365A1 (en) | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| AR091436A1 (es) * | 2012-06-14 | 2015-02-04 | Amgen Inc | Compuestos de azetidina y piperidina utiles como inhibidores de pde10 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JP2013526546A (ja) * | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物 |
| AU2011253058A1 (en) * | 2010-05-13 | 2012-12-06 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
| WO2011143365A1 (en) * | 2010-05-13 | 2011-11-17 | Amgen Inc. | Nitrogen heterocyclic compounds useful as pde10 inhibitors |
| MX2012013128A (es) * | 2010-05-13 | 2013-03-20 | Amgen Inc | Compuestos heterociclicos de nitrogeno como inhibidores de la fosfodiesterasa 10. |
| AR091436A1 (es) * | 2012-06-14 | 2015-02-04 | Amgen Inc | Compuestos de azetidina y piperidina utiles como inhibidores de pde10 |
-
2013
- 2013-06-13 AR ARP130102085 patent/AR091436A1/es unknown
- 2013-06-13 UY UY0001034858A patent/UY34858A/es not_active Application Discontinuation
- 2013-06-14 PE PE2014002438A patent/PE20150348A1/es not_active Application Discontinuation
- 2013-06-14 MX MX2014014924A patent/MX2014014924A/es unknown
- 2013-06-14 WO PCT/US2013/045768 patent/WO2013188724A1/en not_active Ceased
- 2013-06-14 BR BR112014031368A patent/BR112014031368A2/pt not_active IP Right Cessation
- 2013-06-14 EA EA201590014A patent/EA201590014A1/ru unknown
- 2013-06-14 HK HK15104351.8A patent/HK1203935A1/xx unknown
- 2013-06-14 KR KR1020147035700A patent/KR20150023417A/ko not_active Withdrawn
- 2013-06-14 CA CA2875802A patent/CA2875802A1/en not_active Abandoned
- 2013-06-14 AU AU2013274153A patent/AU2013274153B2/en not_active Expired - Fee Related
- 2013-06-14 CN CN201380031076.4A patent/CN104619694A/zh active Pending
- 2013-06-14 AP AP2014008136A patent/AP2014008136A0/xx unknown
- 2013-06-14 SG SG11201408168UA patent/SG11201408168UA/en unknown
- 2013-06-14 JP JP2015517445A patent/JP2015519402A/ja active Pending
- 2013-06-14 US US13/917,699 patent/US8691986B2/en active Active
- 2013-06-14 EP EP13731237.7A patent/EP2864317A1/en not_active Withdrawn
- 2013-06-14 MA MA37748A patent/MA37748B1/fr unknown
- 2013-06-14 TW TW102121229A patent/TWI508959B/zh not_active IP Right Cessation
-
2014
- 2014-01-31 US US14/170,146 patent/US9303028B2/en active Active
- 2014-11-25 IL IL235901A patent/IL235901A0/en not_active IP Right Cessation
- 2014-12-04 TN TN2014000510A patent/TN2014000510A1/fr unknown
- 2014-12-11 PH PH12014502780A patent/PH12014502780A1/en unknown
- 2014-12-12 CL CL2014003391A patent/CL2014003391A1/es unknown
-
2015
- 2015-01-08 CO CO15003862A patent/CO7160011A2/es unknown
- 2015-01-13 CR CR20150012A patent/CR20150012A/es unknown
-
2016
- 2016-03-01 US US15/058,023 patent/US9493459B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160176874A1 (en) | 2016-06-23 |
| KR20150023417A (ko) | 2015-03-05 |
| AU2013274153B2 (en) | 2016-05-19 |
| US20140148435A1 (en) | 2014-05-29 |
| US9303028B2 (en) | 2016-04-05 |
| CR20150012A (es) | 2015-02-11 |
| US20130338138A1 (en) | 2013-12-19 |
| US9493459B2 (en) | 2016-11-15 |
| UY34858A (es) | 2013-11-29 |
| CO7160011A2 (es) | 2015-01-15 |
| MA37748A1 (fr) | 2016-11-30 |
| AR091436A1 (es) | 2015-02-04 |
| PE20150348A1 (es) | 2015-03-04 |
| WO2013188724A1 (en) | 2013-12-19 |
| JP2015519402A (ja) | 2015-07-09 |
| BR112014031368A2 (pt) | 2017-06-27 |
| CN104619694A (zh) | 2015-05-13 |
| PH12014502780A1 (en) | 2015-02-02 |
| TN2014000510A1 (en) | 2016-03-30 |
| EP2864317A1 (en) | 2015-04-29 |
| MA37748B1 (fr) | 2017-07-31 |
| TW201412729A (zh) | 2014-04-01 |
| IL235901A0 (en) | 2015-09-24 |
| AU2013274153A1 (en) | 2014-12-18 |
| US8691986B2 (en) | 2014-04-08 |
| AP2014008136A0 (en) | 2014-12-31 |
| CL2014003391A1 (es) | 2015-07-10 |
| TWI508959B (zh) | 2015-11-21 |
| EA201590014A1 (ru) | 2015-04-30 |
| CA2875802A1 (en) | 2013-12-19 |
| MX2014014924A (es) | 2015-03-09 |
| HK1203935A1 (en) | 2015-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201803726VA (en) | Method for applying stable coating on silicone hydrogel contact lenses | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201908012SA (en) | Cyclic sulfamide compounds and methods of using same | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
| SG11201407427WA (en) | Extreme pcr | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
| SG11201807720TA (en) | Methods and systems for determining antibiotic susceptibility | |
| SG11201408261UA (en) | Syringe | |
| SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201900744SA (en) | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them | |
| SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib |